PMV Pharmaceuticals, Inc.
PMVP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | -0.03 | 0.00 | 0.00 |
| FCF Yield | -26.71% | -33.22% | -32.26% | -21.47% |
| EV / EBITDA | -1.84 | -0.57 | -0.30 | -1.52 |
| Quality | ||||
| ROIC | -18.47% | -16.15% | -11.88% | -14.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.86 | 1.05 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -8.22% | -0.24% | -9.29% | 0.73% |
| Safety | ||||
| Net Debt / EBITDA | 1.68 | 2.04 | 2.33 | 1.58 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,559.69 | -7,306.88 | 0.00 | 0.00 |